Business Context and Reporting Period
Company: Rein Therapeutics, Inc. (RNTX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2025
Subject: Update on FDA Clinical Hold regarding the U.S. Phase 2 RENEW clinical trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Update
The Company received preliminary meeting comments from the FDA regarding a Clinical Hold Letter issued on July 8, 2025. Key developments include:
- Resolution of Toxicology Concerns: The FDA agreed that mucous cell hyperplasia/hypertrophy (MCH/H) findings in GLP rat studies are not dose-limiting for the proposed 24-week protocol at doses up to 10 mg/day.
- No New Toxicity Study Required: The FDA confirmed that a new GLP toxicity study in rats is not required to lift the hold.
- Required Actions: The Company must prepare a Complete Response Letter (CRL) addressing safety concerns, including amended study reports, supplemental nonclinical justification, updated clinical safety/pharmacokinetics/pharmacodynamics data, and an updated protocol.
- Protocol Enhancements: The updated protocol must include augmented safety monitoring (spirometry assessments), treatment discontinuation criteria, and unblinded Data and Safety Monitoring Board reviews incorporating spirometry data.
- Additional Data: The FDA encouraged the submission of publications and reports using New Approach Methodologies, such as human precision-cut lung slices and organoids derived from IPF patients.
Guidance, Outlook, and Risks
Management Outlook: The Company is preparing the CRL in accordance with FDA recommendations and hopes to submit it within the next few weeks. Management is hopeful this submission will lead to a timely release of the clinical hold.
Risks and Contingencies:
- Uncertainty regarding whether the CRL will successfully resolve the clinical hold or if further actions/studies will be required.
- Potential delays in the RENEW Phase 2 trial impacting cash resources.
- Risk of insufficient cash resources to fund the trial and operations if the hold is not lifted promptly.
- Standard pharmaceutical development risks, including patient enrollment challenges and the possibility that early trial results may not be replicated.
Investor Verification Checklist
- Verify the submission date of the Complete Response Letter (CRL) to the FDA.
- Monitor for the FDA's official decision on the release of the Clinical Hold.
- Review the Company's cash runway and capital requirements in light of potential trial delays.
- Confirm the specific details of the updated clinical protocol, particularly regarding safety monitoring and discontinuation criteria.